Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30050783 | 0.98 | TGFBR1 (0.36) | TGFBR1PIK3CDDYRK1AEGFRKDR | |
| SCHEMBL23291684 | 0.80 | TGFBR1 (0.44) | TGFBR1PIK3CDDYRK1ATNIKSCD | |
| SCHEMBL29655510 | 0.75 | TGFBR1 (0.46) | TGFBR1PIK3CDDYRK1AEGFRKDR | |
| SCHEMBL260059 | 0.75 | DNMT1 (0.39) | TGFBR1PIK3CDDYRK1AEGFRKDR | |
| SCHEMBL24167389 | 0.75 | TGFBR1 (0.37) | TGFBR1PIK3CDDYRK1APDE10AMAP4K4 | |
| SCHEMBL29655527 | 0.75 | EGLN2 (0.41) | TGFBR1PIK3CDDYRK1AEGFRKDR | |
| SCHEMBL29655509 | 0.75 | TGFBR1 (0.46) | TGFBR1PIK3CDDYRK1AEGFRKDR | |
| SCHEMBL23432223 | 0.75 | TGFBR1 (0.40) | TGFBR1PIK3CDDYRK1APDE10AMAP4K4 | |
| Hydrochloric Acid SCHEMBL23005314 | 0.73 | TGFBR1 (0.36) | TGFBR1PIK3CDDYRK1APDE10AMAP4K4 | |
| Hydrochloric Acid SCHEMBL29974128 | 0.73 | DYRK1A (0.41) | TGFBR1PIK3CDDYRK1AEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368505-A1 | FLUORINE-FREE CLEANING AGENT, PREPARATION METHOD THEREFOR AND USE THEREOF | Tan Kah Kee Innovation Laboratory (CN) | 2024-11-07 | — | — | US | claimed |
| CN-116903615-A | Preparation method of tocartinib and intermediate thereof | 江苏丽源医药有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-114671867-B | Preparation method of tocartinib intermediate 7-hydroxy- [1,2,4] triazolo [1,5-a ] pyridine | 上海法默生物科技有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-116731798-A | Fluorine-free cleaning agent, and preparation method and application thereof | 嘉庚创新实验室 | 2023-09-12 | — | — | CN | claimed |
| WO-2023133876-A1 | FLUORINE-FREE CLEANING AGENT, PREPARATION METHOD THEREFOR AND USE THEREOF | 嘉庚创新实验室 | 2023-07-20 | — | — | WO | claimed |
| CN-114317127-B | Fluorine-free cleaning agent, and preparation method and application thereof | 嘉庚创新实验室 | 2023-07-04 | — | — | CN | claimed |
| CN-116120310-A | Preparation method and detection method of 7-hydroxy- [1,2,4] triazolo [1,5-A ] pyridine | 威智医药有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-114671867-A | Preparation method of 7-hydroxy- [1,2,4] triazolo [1,5-a ] pyridine serving as intermediate of tocainib | 上海法默生物科技有限公司 | 2022-06-28 | — | — | CN | claimed |
| CN-114317127-A | Fluoride-free cleaning agent, and preparation method and application thereof | 嘉庚创新实验室 | 2022-04-12 | — | — | CN | claimed |
| US-12447153-B2 | HER2 mutation inhibitors | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025202889-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2025-10-02 | — | — | WO | disclosed |
| CN-119552161-A | Preparation process of fig. critinib intermediate 4- ([ 1,2,4] triazolo [1,5-a ] pyridine-7-oxy) -3-methylaniline | 神隆医药（常熟）有限公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4506343-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | Voronoi Inc. (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-12171739-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-1971601-B1 | N4-PHENYL-QUINAZOLINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-2090575-A1 | Processes and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives | Array Biopharma, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1971601-A2 | N4-PHENYL-QUINAZOLINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Array Biopharma Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007059257-A2 | N4-PHENYL-QUINAZ0LINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059257-A2 | N4-PHENYL-QUINAZ0LINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171739-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | TGFBR1 900/4885PIK3CD 426/4885DYRK1A 420/4885 |
| US-12447153-B2 | HER2 mutation inhibitors | ERBB2, EGFR, ERBB3 | TGFBR1 191/4885PIK3CD 227/4885DYRK1A 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.